Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04765137 · ClinicalTrials.gov registry record · Phase 2

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

A Phase 2 study of Mild Cognitive Impairment, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT04765137 is a Phase 2 study of Mild Cognitive Impairment that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04765137, a Phase 2 study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Conditions Studied

Interventions

  • DRUG Atorvastatin Oral Tablet

Study Locations (1)

Maryland

  • Johns Hopkins University, Bayview Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-05-21
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT04765137

The ClinicalTrials.gov registry entry for NCT04765137 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin Oral Tablet is the first listed.

NCT04765137 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04765137 about?

NCT04765137 is a clinical study titled "Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)". The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

What is the current status of trial NCT04765137?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-05-21. Estimated completion is 2026-12-31.

What conditions does trial NCT04765137 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT04765137?

The interventions under investigation include: Atorvastatin Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT04765137?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04765137 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.